Siddharth M Patel, Yu Mi Kang, KyungAh Im, Brendon L Neuen, Stefan D Anker, Deepak L Bhatt, Javed Butler, David Z I Cherney, Brian L Claggett, Robert A Fletcher, William G Herrington, Silvio E Inzucchi, Meg J Jardine, Kenneth W Mahaffey, Darren K McGuire, John J V McMurray, Bruce Neal, Milton Packer, Vlado Perkovic, Scott D Solomon, Natalie Staplin, Muthiah Vaduganathan, Christoph Wanner, David C Wheeler, Faiez Zannad, Yujie Zhao, Hiddo J L Heerspink, Marc S Sabatine, Stephen D Wiviott
BACKGROUND: Sodium glucose co-transporter 2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear. METHODS: This was a collaborative trial-level meta-analysis from the SGLT2i meta-analysis cardio-renal trialists consortium, which includes all phase 3, placebo-controlled, outcomes trials of SGLT2i across three patient populations (diabetes at high risk for atherosclerotic cardiovascular disease [ASCVD], heart failure [HF], or chronic kidney disease [CKD])...
April 7, 2024: Circulation